Company
Ge Healthcare
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
47
12 still marketed
Novel approvals
18
Approvals since 2021
2
Originals and new uses
Phase 3 trials
21
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Vizamyl new use Jun 23, 2025
- Optison new use May 9, 2025
- Cerianna approved NovelMay 20, 2020
- Visipaque 270 new use Priority reviewApr 5, 2017
- Visipaque 270 new use Priority reviewApr 5, 2017
- Vizamyl approved NovelOct 25, 2013
- Adreview new use Mar 20, 2013
- Optison new use Aug 17, 2012
- Adreview approved NovelPriority reviewOrphanSep 19, 2008
- Omniscan approved Sep 5, 2007
Drugs in development (1)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- GE-287Phase 21 trial
GE Healthcare · Cognitive Dysfunction
Recruiting Phase 3 trials
Largest first.
- A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult PatientsPivotal-lookingRecruiting
GE HealthcareIndustry
NCT07472491 · 640 participants (planned) · Start Apr 1, 2026 · Primary completion Nov 30, 2027
Drug: Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL; Gadobutrol · For: Known or Highly Suspected Central Nervous System (CNS) Lesion; Known or Highly Suspected Body (Excluding CNS) Lesion
Sites: Rochester, Minnesota; The Woodlands, Texas; Tbilisi, Georgia · 7 sites in all
- Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)Pivotal-lookingRecruiting
GE HealthcareIndustry
NCT07219238 · 175 participants (planned) · Start Oct 2026 · Primary completion Jun 2029
Drug: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) · For: Colorectal Cancer; Gastric Cancers; Ovarian Cancers and 1 more
Sites: Grand Rapids, Michigan; Stockholm, Sweden
Marketed drugs (12)
Newest FDA action first.
- Vizamyl Flutemetamol F-18 · 2013
- Optison Albumin Human · 1997
- Omniscan Gadodiamide · 1993
- Omnipaque 140 Iohexol · 1985
- Omnipaque 350 Iohexol · 1995
- Cerianna Fluoroestradiol F-18 · 2020
- Visipaque 270 Iodixanol · 1996
- Visipaque 270 Iodixanol · 1997
- Indium In 111 Oxyquinoline Indium In-111 Oxyquinoline · 1985
- Adreview Iobenguane Sulfate I-123 · 2008
- Ceretec Technetium Tc-99m Exametazime Kit · 1988
- Mpi Indium Dtpa In 111 Indium In-111 Pentetate Disodium · 1982
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.